ENTX
Entera Bio LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$61.04M
P/E Ratio
—
EPS
$-0.26
Beta
1.55
52W High
$3.22
52W Low
$0.91
50-Day MA
$1.20
200-Day MA
$1.76
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-12.48M |
| Operating Margin | 0.00% |
| Return on Equity | -82.30% |
| Return on Assets | -45.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.23 |
| Price-to-Book | 5.69 |
| Price-to-Sales (TTM) | 1547.08 |
| EV/Revenue | 1527.79 |
| EV/EBITDA | -1.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $49.23M |
| Float | $40.47M |
| % Insiders | 23.49% |
| % Institutions | 16.00% |
Historical Volatility
HV 10-Day
78.94%
HV 20-Day
82.78%
HV 30-Day
83.15%
HV 60-Day
99.15%
HV Rank
58.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($9.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026